War on Drugs

The War on Drugs is the punitive framework the book contrasts with treating addiction as a public-health problem. Its consequences appear not only in arrests and prison sentences, but also in unequal access to pain medication, the conditions people face after release, and the different standards applied to individual drug offenders and pharmaceutical companies. The account’s central tension is that calls to address opioid addiction through treatment coexist with a criminal system that continues to punish many people who sell drugs, especially people of color.

From public health to criminalization

The book traces the decision to treat addiction and dependence primarily as a crime problem to the 1970s. Bryan Stevenson describes the turn as politically enabled by fear and anger, and by the appeal of criminalizing a new community. The policy choice is presented not as an inevitable response to drugs, but as a framework that directs resources and public judgment toward punishment rather than care.

That framework shapes the contrast between two accounts of drug enforcement. Bill Metcalf, the agent whose work helped secure Ronnie Jones’s twenty-three-year prison sentence, drew inspiration from anti-drug messaging that pictured the brain as damaged by drugs and urged people simply to refuse them. Michelle Alexander and Bryan Stevenson, by contrast, saw mandatory minimums, three-strikes laws, the end of parole, and stop-and-frisk policing as instruments of racialized punishment. The dispute is not only over the effectiveness of particular laws; it is over which people are understood as patients in need of help and which are treated as criminal threats.

Race, prescribing, and punishment

The account places racial inequality in drug enforcement alongside inequality in medical care. In Roanoke, Virginia, heroin had long been treated as an inner-city drug associated with a small, largely Black population. Don Wolthuis recalled that heroin use was relatively invisible to the wider public and that, among the area’s mostly African American heroin users and dealers, a common expectation was that white people would report sellers to the police. The book contrasts that earlier picture with the later spread of heroin use beyond the group with which it had been associated.

The criminal consequences fall unevenly. Ronnie Jones was serving his third prison term, and his experience illustrates the loop the book describes: a felony record can block access to mainstream work, increasing the likelihood of unemployment and return to prison. The account cites a 75 percent recidivism rate for drug-involved offenders and reports that three-quarters of federal drug offenders are Black or Hispanic, while 57 percent of people imprisoned for drug offenses in state systems are people of color. It also argues that the appeal to stop arresting people to solve the opioid epidemic has often been applied more readily to mostly white opioid users committing property crimes to stave off withdrawal than to people such as Ronnie, imprisoned for heroin distribution. The book notes that people of color arrested for selling drugs were statistically less likely to use or deal than the white opioid users invoked in that contrast.

Medical decisions form another part of this unequal pattern. Data from the Centers for Disease Control and Prevention in 2014 addressed why Black people had not been caught up in opioid addiction to the same degree: doctors prescribed them painkillers at much lower rates than white patients, reflecting distrust that patients of color would misuse opioids. The book presents the resulting disparity as a grim paradox: racial stereotyping may have limited exposure to prescription opioids even as racialized enforcement exposed people of color to harsher criminal penalties. By 2014, the overdose death rate among young white people had risen to three times its 2002 level, while the rate for people of color was described as relatively unchanged. The contrast indicts unequal prescribing without treating unequal exposure as protection that came without cost.

Prison, reentry, and alternatives

The book extends its analysis beyond sentencing to the transition out of prison. It raises, as a question rather than a settled causal finding, whether the movement of roughly ten thousand people each week from state and federal prisons into communities could help fan the opioid crisis. For people returning with felony records, the barriers to employment and housing can compound the same instability that contributes to repeated incarceration. Ronnie’s experience is offered as a case in point, not as proof that every release leads to the same outcome.

Alternative approaches described in the account combine diversion, treatment, and practical support. In Seattle, the Equal Justice Initiative sends clients to cities where jobs and harm-reduction services are more available. Police can divert addicted people accused of low-level drug or prostitution offenses before booking them, connecting them instead with housing, case management, and employment services. The approach addresses both sides of street-level dealing: the need for former dealers to find legitimate work and the demand for drugs that dealing serves. Bryan Stevenson argues that reducing the prison population and investing part of the resulting savings in treatment could improve people’s chances of success.

A drug court in Winchester, Virginia, offered a more local example of treatment-oriented reentry. It was designed to connect offenders with treatment, including Medication-assisted treatment, as well as free housing and taxi vouchers to help them get to work in a rural area. These measures recognize that treatment access depends on more than a formal referral: housing and transportation can determine whether a person can reach care or keep a job.

The same implementation problem appears in emergency care. After a rise in overdose cases, local advocates sought a smooth transfer from hospital emergency departments to outpatient Medication-assisted treatment and counseling, modeled on protocols in Ontario. Cheri Hartman helped develop a similar handoff in Roanoke, Virginia, but shortages of providers, detoxification and treatment beds, and bureaucratic, financial, and legal obstacles impeded it. A grant application and plans to train peer recovery specialists offered possible routes forward, but the state program would take months to operate. In the meantime, hospital social workers referred some revived overdose patients to the Hope Initiative, including people who had passed out while driving. The episode shows how a public-health alternative can be recognized as necessary yet remain difficult to deliver amid fragmented services and limited capacity.

Unequal accountability and the policy’s legacy

The book also sets the punishment of street-level offenders against the handling of corporate conduct. Purdue Pharma’s 1995 application to the U.S. Food and Drug Administration described risks that included the immediate release of the drug if tablets were crushed, withdrawal symptoms observed during clinical trials, and the recoverability of 68 percent of the oxycodone in a crushed pill when liquefied and injected. Although Purdue later claimed it had not known of abuse problems until February 2000, the approval record contained those warnings. The account also notes that the examiner who approved the application, Curtis Wright, later worked as a consultant for Purdue Pharma.

Other evidence raised questions about the boundary between regulators and industry. Beginning in 2002, FDA regulators and pharmaceutical executives held private meetings at hotels through an industry-funded nonprofit. The practice of enriched enrollment allowed companies to remove study participants who did not respond well to a drug, potentially tilting the evidence submitted for approval away from a full account of a drug’s effects. Separately, the American Pain Society and the American Academy of Pain Medicine advocated broader opioid use for chronic pain while receiving millions of dollars from drug companies. A 2012 Senate investigation examined those relationships, including the role of the American Pain Foundation and Purdue Pharma, but its findings remained sealed in the Senate Finance Committee’s office.

The federal case against Purdue Pharma provides a further contrast. In 2006, prosecutors’ contemplated charges reportedly included felony counts beyond misbranding, but the case was narrowed as it passed through the Department of Justice headquarters, amid lobbying against felony charges for company executives. The government initially proposed a billion-dollar payment, while Purdue Pharma first offered ten million dollars. On the night before the plea deadline, a senior Justice Department official contacted John Brownlee at home at the request of a Purdue lawyer, seeking more time for the company. Purdue Pharma accepted the plea agreement later that night rather than risk more serious charges or a trial in western Virginia. The book does not equate corporate prosecution with individual imprisonment; it uses the contrast to expose how differently the system can negotiate accountability depending on who is being prosecuted.

Across these episodes, the War on Drugs appears not as a single policy with uniform effects, but as a durable way of sorting people and problems. It can frame addiction as a disease when discussing treatment for some opioid users, yet preserve imprisonment and exclusion for others; it can make treatment contingent on scarce local resources while allowing corporate cases to be narrowed through negotiation. The alternatives described—diversion, Medication-assisted treatment, housing, transportation, and coordinated care—show what a health-centered response might require, while the repeated gaps between plans and services reveal how difficult it is to replace punishment with care.